139 related articles for article (PubMed ID: 15061445)
1. Potential reduction exposure products and FDA tobacco and regulation: a CNS call to action.
Heath J; Andrews J; Balkstra CR
Clin Nurse Spec; 2004; 18(1):40-8; quiz 49-50. PubMed ID: 15061445
[TBL] [Abstract][Full Text] [Related]
2. [Harm reduction strategy in tobacco control].
Gorini G
Epidemiol Prev; 2011; 35(3-4 Suppl 1):19-32. PubMed ID: 21926451
[TBL] [Abstract][Full Text] [Related]
3. Surveillance of tobacco industry retail marketing activities of reduced harm products.
Slater S; Giovino G; Chaloupka F
Nicotine Tob Res; 2008 Jan; 10(1):187-93. PubMed ID: 18188759
[TBL] [Abstract][Full Text] [Related]
4. No sisyphean task: how the FDA can regulate electronic cigarettes.
Paradise J
Yale J Health Policy Law Ethics; 2013; 13(2):326-74. PubMed ID: 24340824
[TBL] [Abstract][Full Text] [Related]
5. Effect of smokeless tobacco product marketing and use on population harm from tobacco use policy perspective for tobacco-risk reduction.
Kozlowski LT
Am J Prev Med; 2007 Dec; 33(6 Suppl):S379-86. PubMed ID: 18021913
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the acute effects of oral, non-combustible potential reduced exposure products marketed to smokers.
Cobb CO; Weaver MF; Eissenberg T
Tob Control; 2010 Oct; 19(5):367-73. PubMed ID: 19346218
[TBL] [Abstract][Full Text] [Related]
7. Pilot study on lower nitrosamine smokeless tobacco products compared with medicinal nicotine.
Mendoza-Baumgart MI; Tulunay OE; Hecht SS; Zhang Y; Murphy S; Le C; Jensen J; Hatsukami DK
Nicotine Tob Res; 2007 Dec; 9(12):1309-23. PubMed ID: 18058349
[TBL] [Abstract][Full Text] [Related]
8. Electronic cigarettes and alternative nicotine products.
Hanson K
NCSL Legisbrief; 2014 Jul; 22(26):1-2. PubMed ID: 25514811
[TBL] [Abstract][Full Text] [Related]
9. The legal and scientific basis for FDA's assertion of jurisdiction over cigarettes and smokeless tobacco.
Kessler DA; Barnett PS; Witt A; Zeller MR; Mande JR; Schultz WB
JAMA; 1997 Feb; 277(5):405-9. PubMed ID: 9010173
[TBL] [Abstract][Full Text] [Related]
10. Regulating E-cigarettes: a rule proposed by the FDA aims to extend authority to E-cigarettes, other tobacco products.
Printz C
Cancer; 2014 Jul; 120(14):2069-71. PubMed ID: 24985247
[No Abstract] [Full Text] [Related]
11. Nicotine pharmacokinetics and subjective effects of three potential reduced exposure products, moist snuff and nicotine lozenge.
Kotlyar M; Mendoza-Baumgart MI; Li ZZ; Pentel PR; Barnett BC; Feuer RM; Smith EA; Hatsukami DK
Tob Control; 2007 Apr; 16(2):138-42. PubMed ID: 17400953
[TBL] [Abstract][Full Text] [Related]
12. Emerging nicotine delivery products. Implications for public health.
Benowitz NL
Ann Am Thorac Soc; 2014 Feb; 11(2):231-5. PubMed ID: 24575992
[TBL] [Abstract][Full Text] [Related]
13. Electronic cigarettes: the good, the bad and the unknown.
Varkey B
Curr Opin Pulm Med; 2014 Mar; 20(2):125-6. PubMed ID: 24401853
[No Abstract] [Full Text] [Related]
14. Harm reduction policies for tobacco users.
Gartner C; Hall W
Int J Drug Policy; 2010 Mar; 21(2):129-30. PubMed ID: 19944582
[TBL] [Abstract][Full Text] [Related]
15. Literature review and summary of perceptions, attitudes, beliefs, and marketing of potentially reduced exposure products: communication implications.
Pederson LL; Nelson DE
Nicotine Tob Res; 2007 May; 9(5):525-34. PubMed ID: 17454709
[TBL] [Abstract][Full Text] [Related]
16. Does dual use jeopardize the potential role of smokeless tobacco in harm reduction?
Frost-Pineda K; Appleton S; Fisher M; Fox K; Gaworski CL
Nicotine Tob Res; 2010 Nov; 12(11):1055-67. PubMed ID: 20847148
[TBL] [Abstract][Full Text] [Related]
17. European Union policy on smokeless tobacco: a statement in favour of evidence based regulation for public health.
Bates C; Fagerström K; Jarvis MJ; Kunze M; McNeill A; Ramström L
Tob Control; 2003 Dec; 12(4):360-7. PubMed ID: 14660767
[TBL] [Abstract][Full Text] [Related]
18. Obsolete tobacco control themes can be hazardous to public health: the need for updating views on absolute product risks and harm reduction.
Kozlowski LT; Abrams DB
BMC Public Health; 2016 May; 16():432. PubMed ID: 27221096
[TBL] [Abstract][Full Text] [Related]
19. FDA considering data on long-term use of nicotine replacement therapy products.
Kuehn BM
JAMA; 2010 Dec; 304(23):2580. PubMed ID: 21156943
[No Abstract] [Full Text] [Related]
20. FDA's new plan to reduce the nicotine in cigarettes to sub-addictive levels could be a game-changer.
Proctor RN
Tob Control; 2016 Sep; 26(5):487-488. PubMed ID: 28831030
[No Abstract] [Full Text] [Related]
[Next] [New Search]
